Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Rating) CEO James F. Oliviero III sold 3,817 shares of the stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $6.75, for a total transaction of $25,764.75. Following the completion of the sale, the chief executive officer now directly owns 192,382 shares of the company’s stock, valued at approximately $1,298,578.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Checkpoint Therapeutics Stock Performance
Shares of CKPT stock opened at $7.60 on Friday. The firm’s 50 day moving average price is $3.16 and its 200-day moving average price is $1.84. Checkpoint Therapeutics, Inc. has a one year low of $3.56 and a one year high of $27.00. The firm has a market cap of $70.68 million, a P/E ratio of -0.87 and a beta of 1.54.
Checkpoint Therapeutics (NASDAQ:CKPT – Get Rating) last released its earnings results on Tuesday, November 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.07 million. Checkpoint Therapeutics had a negative net margin of 53,252.24% and a negative return on equity of 508.89%. As a group, research analysts predict that Checkpoint Therapeutics, Inc. will post -5.91 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Institutional Investors Weigh In On Checkpoint Therapeutics
A number of hedge funds have recently added to or reduced their stakes in CKPT. Morgan Jess S & Co. Inc. lifted its holdings in Checkpoint Therapeutics by 66.6% during the 3rd quarter. Morgan Jess S & Co. Inc. now owns 1,894,694 shares of the company’s stock worth $1,970,000 after buying an additional 757,372 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Checkpoint Therapeutics by 307.5% during the 1st quarter. Renaissance Technologies LLC now owns 923,035 shares of the company’s stock worth $1,634,000 after buying an additional 696,535 shares in the last quarter. Spotlight Asset Group Inc. acquired a new stake in Checkpoint Therapeutics during the 3rd quarter worth approximately $622,000. PVG Asset Management Corp acquired a new stake in Checkpoint Therapeutics during the 3rd quarter worth approximately $408,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Checkpoint Therapeutics during the 1st quarter worth approximately $292,000.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
- Get a free copy of the StockNews.com research report on Checkpoint Therapeutics (CKPT)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.